Gariani Karim, Jornayvaz François R
Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, HUG, 1211 Genève 14.
Rev Med Suisse. 2021 Jan 27;17(723):188-191.
Diabetes is a rapidly evolving discipline, numerous new molecules and recommendations are available. However, these rapid changes are sometimes difficult to follow for general practitioners. Metformin remains the cornerstone of type 2 diabetes treatment after lifestyle modifications, which should always be encouraged before medications. Currently, the best classes to add after metformin seem to be SGLT2 inhibitors and GLP-1 receptor agonists, as these molecules showed some cardiovascular and renal beneficial effects in dedicated studies. Nevertheless, the current pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in trouble finding the right medication. This article will highlight novelties in the field of diabetes during the year 2020.
糖尿病是一个快速发展的学科，有众多新的药物分子和治疗建议。然而，全科医生有时难以跟上这些快速变化。在进行生活方式调整后，二甲双胍仍然是2型糖尿病治疗的基石，在用药前应始终鼓励进行生活方式调整。目前，在二甲双胍之后添加的最佳药物类别似乎是钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂，因为这些药物分子在专门研究中显示出一些心血管和肾脏方面的有益作用。尽管如此，当前药理学上的药物过多情况却反常地与临床惰性相关，因为全科医生在寻找合适药物时可能会遇到困难。本文将重点介绍2020年糖尿病领域的新进展。
